3M 2000–2007: Did the Efficiency Program Show Up as an Innovation Fade in the Filings?

Stagnation Slaughters. Strategy Saves. Speed Scales.

Scope: A filings test of one company over ten years: 3M Co. (Minnesota Mining and Manufacturing Company until 2002), fiscal 1999 through 2008. Every number comes from 3M’s annual reports on SEC EDGAR, linked at the bottom. Nobody is graded, and this isn’t a profile of any chief executive. Windows are fixed in advance: fiscal 1999–2000 is the baseline, 2001–2005 the program window, and 2006–2007 (with 2008 as a check) the first years after the leadership change. Dollars are in millions unless marked; the fiscal year is the calendar year.

The story is well known. An outsider takes over a famous inventor in 2001, brings in Six Sigma and a hard cost program, and margins jump. A few years later the business press asks whether all that discipline drained the creativity out of the place. Retold often enough, it sounds settled. It isn’t. Much of it rests on interviews and on an internal new-product ratio that the 10-Ks examined here don’t report. So this piece sets the interviews aside and asks a narrower question the filings can answer.

The question: during and after 3M’s 2001–2005 efficiency program, did the company’s own filings show research spending and margins holding, improving, or fading?

Short answer: A drift, not a collapse, and it didn’t reverse after the leadership change. Research, development and related expense fell from 6.7% of sales in 1999 to about 6.0% in 2003 and about 5.6% in 2007–2008, after adjusting for three definition changes and one-off items. In dollars, research was never slashed: it dipped about 3% from 2000 to 2002, then grew more slowly than sales. The line that really got cut was capital spending, from 6.7% of sales in 2000 to 3.7% in 2003, and that cut was largely reversed by 2007. Operating margin, excluding items 3M flagged, rose from about 18% to about 22.5% and held. No 10-K reports a new-product sales ratio, so the filings can’t show whether invention itself suffered.

What an Annual Report Can and Can’t See

The usual version of this question is “why do operational-excellence programs fade after six to twelve months?” Annual reports can’t answer that. A 10-K gives one set of numbers a year, and a six-month slump disappears into the annual total. Nothing here tests short-term fade. What ten annual reports can test is multi-year sustainment: whether the ratios a cost program was meant to improve stayed improved, and whether the ratios critics said it would damage actually moved. The test runs on four lines: research spending as a share of sales, organic sales volume, operating margin and capital spending.

The Timeline the Filings Give You

Date Event Source
Dec 6, 2000 Form 8-K announces W. James McNerney, Jr. elected chairman and CEO, effective January 1, 2001 FY2000 10-K
June 2001 Restructuring plan approved FY2002 10-K
2003 R&D realigned; single global Corporate Research Laboratory set up FY2003 and FY2004 10-Ks
Jun 29, 2005 Letter agreement between 3M and McNerney (Form 8-K dated June 30, 2005) FY2005 10-K exhibit list
Dec 6, 2005 Employment agreement between 3M and George W. Buckley, listed as elected chairman, president and CEO in 2005 FY2005 10-K
Feb 21, 2006 FY2005 10-K filed; “3M Acceleration” and the named initiative list no longer appear FY2005 10-K
Dec 2006–Jan 2007 Global branded pharmaceuticals business sold FY2006 and FY2007 10-Ks
June 2007 BusinessWeek article on efficiency versus creativity at 3M Journalism (context only)

[Inference] Fiscal 2005 spans the leadership change. It sits in the program window because initiative benefits were still reported for 2005, but it shouldn’t be read as either man’s year.

Step 1: What 3M Said the Program Was

Start with the company’s own words, not the press’s. The 10-K for fiscal 2000, filed seven weeks after the new CEO started, listed longer-term programs “in the initial stages of implementation.” Two of them bear directly on this question:

  • [Company assertion] “An initiative to more effectively prioritize 3M’s significant research and development commercialization investments across all businesses to further strengthen returns.”
  • [Company assertion] “Adoption and concentration of Six Sigma across the company – one way of doing business across all of 3M that will particularly help direct costs and cash.”

The fiscal 2002 10-K describes five corporate initiatives: Six Sigma, Global Sourcing Effectiveness, 3M Acceleration, Indirect Cost Reduction and eProductivity. The one aimed at the labs was 3M Acceleration: [Company assertion] “3M Acceleration reallocates research and development resources to larger, more global projects.” By fiscal 2004 the description had widened: [Company assertion] “Through its 3M Acceleration initiative, the Company is driving toward more and better new product ideas and faster, more impactful new product introductions, along with reallocating research and development resources to larger, more global projects.”

[Fact] Six Sigma here is 3M’s own disclosed tool, named in its filings. It isn’t a framework from this site, and nothing below claims 3M used one.

[Company assertion] 3M estimated the initiatives’ benefit to operating income at “more than $500 million” in 2002, “more than $400 million” in 2003, “over $400 million” in 2004 and “approximately $400 million” in 2005. [Inference] That’s at least $1,700 million of claimed benefit, on top of separately estimated restructuring savings. These are management estimates, and the fiscal 2003 10-K adds: “There can be no assurance that all of the estimated cost savings from such activities will be realized.” They say nothing about research output.

[Company assertion] The fiscal 2002 10-K on overhead: “This improvement in SG&A costs was the result of implementing Six Sigma, indirect cost control programs (controlling those expenses not directly associated with 3M products and services) and employment reductions under the restructuring plan approved in June 2001.”

Step 2: Three Definition Changes to Fix Before You Compute Anything

This is where quick takes on 3M go wrong. “Research, development and related expenses” wasn’t measured the same way across the decade, and lining up numbers from different filings produces trends that are really accounting changes.

Change First filing Effect on the R&D line
R&D pulled out of cost of sales and shown on its own line; freight billed to customers moved into net sales FY2000 10-K 1999 RD&R restated from $1,038M to $1,056M; 1999 sales from $15,659M to $15,748M
Costs of internally developed patents moved from SG&A into RD&R FY2005 10-K 2003 RD&R +$45M (to $1,147M); 2004 +$51M (to $1,194M)
Stock-based compensation expensed under SFAS No. 123R, prior years adjusted (modified retrospective) FY2006 10-K 2004 RD&R +$52M (to $1,246M); 2005 +$32M (to $1,274M); narrow R&D +$33M and +$20M

Sources: FY1999, FY2000, FY2004, FY2005 and FY2006 10-Ks. Differences are my arithmetic between the same year as reported in two filings.

[Company assertion] The fiscal 2005 note: “Costs of internally developed patents have been reclassified to “Research, development and related expenses” from “Selling, general and administrative expenses”.”

[Inference] Two of the three changes pushed the R&D line up after 2004. Comparing the fiscal 2004 10-K’s $1,143M with the later $1,274M for 2005 shows an 11% jump that is mostly reclassification. The fix is to compare years only on the same basis and lean on the narrow “research and development” figure, which the patent move didn’t touch.

[Fact] 3M discloses that narrower figure every year: research and development “covering basic scientific research and the application of scientific advances” to new and improved products. The fiscal 2000 10-K adds: “Related expenses primarily include technical support provided by the laboratories for existing products.”

Step 3: Research Intensity Across the Three Windows

Year Net sales RD&R, as reported RD&R % of sales, excluding flagged items Narrow R&D Narrow R&D % of sales Basis
1999 15,748 1,056 6.71% 688 4.37% Original
2000 16,724 1,101 6.58% 727 4.35% Original
2001 16,054 1,084 6.63% 745 4.64% Original
2002 16,332 1,070 6.53% 738 4.52% Original
2003 18,232 1,102 6.04% (6.29% patent basis) 749 4.11% Original
2004 20,011 1,143 5.71% (5.97% patent; 6.23% 123R) 759 (792 123R) 3.79% (3.96%) Original / restated
2005 21,167 1,242 (1,274 123R) 5.87% patent; 6.02% 123R 798 (818 123R) 3.77% (3.86%) Patent / 123R
2006 22,923 1,522 5.90% 943 (848 excl. IPR&D) 3.70% 123R
2007 24,462 1,368 5.61% 788 3.22% 123R
2008 25,269 1,404 5.50% 851 3.37% 123R

My calculation from the income statements and R&D notes in the FY2000–FY2008 10-Ks. “Flagged items” are amounts 3M itself identified inside the RD&R line: restructuring of $20M (2001) and $4M (2002); a $95M purchased in-process R&D charge plus $75M of restructuring (2006); a $4M credit (2007); $13M of restructuring and exit costs (2008). Sales for 2000 are as first reported; the FY2002 10-K later restated them to $16,699M, which leaves the ratio at 6.59%.

[Fact] On the original basis, research, development and related expense was 6.71% of sales in 1999 and 6.58% in 2000. It held at about 6.6% and 6.5% in 2001 and 2002, then fell to 6.04% in 2003 and 5.71% in 2004. The company’s own tables confirm the direction: 6.0% in 2003 against 6.5% in 2002 in the fiscal 2003 10-K, and “flat” in 2005 against 2004 in the fiscal 2005 10-K.

[Inference] On every available basis, the ratio is lower at the end of the program window than at the start, and lower again after the transition. The sharpest step down came in 2003, when sales jumped 11.6%. Narrow R&D fell more sharply: 4.37% of sales in 1999, 3.77–3.86% in 2005, 3.22% in 2007.

Step 4: Dollars Versus Denominator

A falling ratio can mean spending was cut or that sales outgrew spending. The filings let you separate the two.

Components of sales change 2001 2002 2003 2004 2005 2006 2007 2008
Core / organic volume −3.5% +1.0% +4.7% +6.2% +3.5% +6.1% +5.1% −2.4%
Acquisitions +2.6% +0.4% +1.9% +0.5% +1.0% +2.1% +2.4% +3.3%
Price +0.3% +0.2% −0.2% −0.7% +0.6% −0.5% −0.2% +0.5%
Divestitures — — — — — — −3.8% −0.3%
Currency translation −3.3% +0.1% +5.2% +3.8% +0.7% +0.6% +3.2% +2.2%
Total sales change −3.9% +1.7% +11.6% +9.8% +5.8% +8.3% +6.7% +3.3%

Sources: FY2002, FY2003, FY2005, FY2007 and FY2008 10-Ks, as reported. For the baseline, the FY2000 10-K reports volume +5% in 1999 and +10% in 2000, without splitting out acquisitions. 3M calls the volume line “core” through 2006 and “organic” from the FY2007 10-K.

  • [Fact] Research, development and related dollars, on the original basis, went from $1,101 million in 2000 to $1,064 million in 2001 and $1,066 million in 2002 after excluding flagged restructuring, down about 3%. They then rose to $1,143 million in 2004, 3.8% above 2000. Sales rose 19.7% over the same four years.
  • [Fact] Narrow R&D went from $688 million in 1999 to $798 million in 2005 (pre-123R basis), up 16.0%, or about 2.5% a year. Sales grew 34.4%, about 5.1% a year.

[Inference] The fall in research intensity is mostly a denominator story. Spending dipped briefly in the 2001–2002 slowdown, then crept up while sales rose faster, helped by a weaker dollar and acquisitions. Not growing research in step with sales is a real choice, but it isn’t the same as cutting the labs.

[Company assertion] The 2003 realignment of R&D is the one disclosed structural change to the labs in this period: “This realignment was designed to develop technologies needed for the future, to more closely align technical resources with business priorities, and to shorten the distance between research and development and 3M’s customers.” The fiscal 2004 10-K adds that the new single Corporate Research Laboratory brought together “more than 600 researchers focused on technology building while also freeing up approximately 400 other 3M technical people to directly support the growth of 3M business units.”

[Inference] The filings don’t say whether those 400 people stayed inside the R&D line. If any moved to other expense lines, part of the 2003–2004 drop is a change in where people were counted. The 10-Ks don’t give enough detail to size it.

Step 5: Did the Margin Gains Hold?

Year Operating income, reported Margin, reported Items 3M flagged Margin excluding flagged items
1999 2,956 18.8% $100M net gain 18.1%
2000 3,058 18.3% $23M net loss 18.4%
2001 2,273 14.2% $504M of charges 17.3%
2002 3,046 18.7% $202M of charges 19.9%
2003 3,713 20.4% $93M litigation charge 20.9%
2004 4,578 (4,326 on 123R basis) 22.9% (21.6%) None flagged 22.9% (21.6%)
2005 5,009 (4,854 on 123R basis) 23.7% (22.9%) None flagged 23.7% (22.9%)
2006 5,696 24.8% $523M net benefit (pharma gain less charges) 22.6%
2007 6,193 25.3% $681M net benefit (gains less charges) 22.5%
2008 5,218 20.6% $269M net charge 21.7%

Sources: FY2000, FY2003, FY2005, FY2007 and FY2008 10-Ks. “Flagged items” are 3M’s own non-recurring, special or gain/restructuring categories, which aren’t GAAP measures. Margins are my calculation.

[Fact] Excluding flagged items, operating margin averaged 18.3% in 1999–2000 and 22.6% in 2006–2007. Reported 2006–2007 margins were higher still because of $1,074 million and $849 million of gains on business sales.

[Inference] The program’s main financial promise, a structurally higher margin, held through the first two years after the transition. The peak was 2005 (22.9% after stock-option expensing); by 2006–2007 the adjusted margin was about 0.4 points lower, while research and capital spending rose. In 2008, when organic volume fell 2.4%, it was 21.7%, still well above the baseline.

[Company assertion] For 2003: “Cost of sales in 2003 benefited from Six Sigma and other projects aimed at improving manufacturing throughput, yield and productivity.”

Step 6: The Line That Actually Got Cut Was Capex

Year Purchases of property, plant and equipment % of sales Year-end employees
1999 1,050 6.7% 70,549
2000 1,115 6.7% 75,026
2001 980 6.1% 71,669
2002 763 4.7% 68,774
2003 677 3.7% 67,072
2004 937 4.7% 67,071
2005 943 4.5% 69,315
2006 1,168 5.1% 75,333
2007 1,422 5.8% 76,239
2008 1,471 5.8% 79,183 (FTE)

Sources: cash flow statements and Item 1 employment figures in the FY1999–FY2008 10-Ks. 1999 capex is as reported in the FY2000 10-K ($1,039M in the FY1999 10-K). Percentages are my calculation.

[Fact] Capital spending fell 22% from 2001 to 2002 and another 11% to 2003. At $677 million, 2003 capex was 39% below 2000’s, and at 3.7% of sales little more than half the baseline rate. It recovered to 4.5–4.7% in 2004–2005, and the fiscal 2005 10-K pointed higher: [Company assertion] “The Company expects to increase both research and development and capital expenditures in 2006, led primarily by growth programs.” Capex reached 5.8% of sales in 2007 and 2008, up 51% in dollars from 2005 to 2007.

[Fact] On headcount, the fiscal 2002 10-K says: “Since March 31, 2001, employment has declined by approximately 8,900 people, with 6,900 of the decline related to the restructuring plan, and 3,500 of the decline due to the integration of acquisitions and attrition.”

[Inference] The investment the program squeezed hardest, and the next team restored most clearly, is capex, not R&D. Capex fell by almost half as a share of sales and came most of the way back. R&D intensity fell by about a sixth and didn’t come back by 2008. Headcount followed the capex pattern: down about 8,000 from 2000 to 2004, then up about 12,100 by 2008, partly through acquisitions.

Step 7: The First Post-Transition Years, Cleaned Up

  • [Fact] 2006 RD&R of $1,522 million included a $95 million in-process R&D charge and $75 million of restructuring. The pharmaceuticals business, sold in December 2006 and January 2007, incurred research, development and related expenses of about $120 million in 2006 and $142 million in 2005. Its 2006 sales were $774 million.
  • [Company assertion] The fiscal 2007 10-K: “Non-pharmaceutical ongoing R&D expenses, after adjusting for the following items, were up approximately 11% in dollars, as the Company continued to aggressively invest in future technologies and growth opportunities.”
  • [Company assertion] The fiscal 2008 10-K, on a year when the ratio stayed at 5.6%: “3M’s long-term commitment to R&D is unchanged, but in the current economic environment 3M is closely scrutinizing all discretionary investments.”

[Inference] Strip out the in-process charge, the restructuring and the pharmaceuticals R&D, and 2006 research spending is about $1,232 million on sales excluding pharmaceuticals of $22,149 million, or 5.56%. 2007’s $1,372 million (excluding a $4 million credit) is about 11% higher, matching the company’s figure. But 5.61% of sales in 2007 and 5.50% in 2008 are no higher than that 2006 base. Research dollars rose after the transition; research intensity didn’t.

Testing the journalism against the filings

Brian Hindo’s June 2007 BusinessWeek article framed the question as a struggle between efficiency and creativity. It’s journalism, not evidence, but its numbers can be checked. The result is mixed.

  • [Journalist claim, confirmed by filings] Capex fell from $980 million to $763 million and then $677 million in 2003, from 6.1% to 3.7% of sales. That matches the 10-Ks.
  • [Journalist claim, roughly confirmed] R&D was held roughly constant from 2001 to 2005 at just over $1 billion. On the original basis, RD&R ran $1,064–1,143 million in 2001–2004 excluding flagged items.
  • [Journalist claim, not visible in filings] The article said the overall R&D budget would grow 20% in 2007, to $1.5 billion. The filed 2007 figure is $1,368 million, about 10% below 2006’s reported $1,522 million and about 11% above 2006 on the company’s cleaned-up basis. The article may have meant a budget or definition the 10-K doesn’t report; the claim stays unconfirmed.
  • [Not used] The article’s figures on the share of sales from recent products don’t appear in the ten 10-Ks, so they aren’t used.

Step 8: What the Filings Can’t Tell You About Invention

“Innovation fade” is a claim about output. Research spending is an input. On output, the ten annual reports are close to silent.

  • [Fact] None of the ten 10-Ks reports a share of sales from new products, a patent-count trend or a pipeline measure. A text search of all ten found no such ratio.
  • [Company assertion] The risk factors repeatedly say growth depends on new products. The fiscal 2003 wording: “The Company’s growth objectives are largely dependent on the timing and market acceptance of its new product offerings, including its ability to renew its pipeline of new products and to bring those products to market.”

[Inference] The closest output proxy in the filings is organic volume growth, which mixes new products, old products and the economy. Core volume averaged about 3.9% a year in 2002–2005 and 5.6% in 2006–2007, then fell 2.4% in 2008. That doesn’t look like a product engine that stalled during the program years. It can’t rule out effects that would show up after 2008, outside this window.

The Verdict the Filings Support

  1. Research intensity faded slowly and stayed faded: about one point of sales on both the broad measure (6.7% to about 5.6%) and the narrow one (4.4% to 3.2–3.4%). The decline started in 2003 and was still there in 2008.
  2. Research dollars weren’t cut, except briefly: down about 3% from 2000 to 2002, then rising.
  3. The margin gains held: about 18% before, about 22.5% two years after, excluding flagged items.
  4. Capex was cut hard, then restored: 6.7% of sales to 3.7% and back to 5.8%.
  5. Innovation output isn’t testable from these filings: no new-product ratio is reported, and organic volume doesn’t show a stall.

[Editorial] So the answer to the title question is “partly, and not the way the story usually goes.” The filings support a sustained drop in research intensity that outlasted the program and the leadership change. They don’t support “innovation collapsed,” and they don’t show R&D being slashed. The biggest squeeze was on plant and equipment, and that one was reversed.

Disconfirming Evidence

  • [Fact] Research dollars fell only about 3% in 2001–2002, a slowdown in which sales also fell 3.9% in 2001. A program that gutted the labs would have shown a deeper cut.
  • [Fact] Core volume grew 4.7%, 6.2% and 3.5% in 2003–2005, the heart of the program window. That’s not the sales record of a company that had stopped producing things customers wanted.
  • [Fact] The ratio kept falling after 2005. If the program caused the drop and the next team reversed the program, it should have rebounded. It didn’t, so either something else drove it or the effect persisted.
  • [Fact] Two of the three definition changes raised the R&D line. Mixing bases can hide the decline or manufacture a rebound.
  • [Limit] There’s no peer set. If other diversified manufacturers drifted the same way, part of the decline is an industry pattern.

Alternative explanation: The decline in intensity could be mostly mix and currency rather than a choice about the labs. Summing the yearly figures for 2003–2007, currency translation added about 13.5 points of sales growth and acquisitions about 8 more. If acquired businesses and faster-growing international sales carried less research per dollar, intensity would fall with no change in lab budgets. The filings give these effects on sales but not on R&D, so it can’t be settled. [Inference] It fits the dollar numbers at least as well as “the program starved the labs.” It can’t explain the brief 2000–2002 dollar dip, which lines up with the restructuring.

Sensitivity: On the original basis, the 1999–2000 average to 2004 drop is about 0.9 points (6.65% to 5.71%). On the patent basis, 2003 to 2005 is 6.29% to 5.87%; on the 123R basis, 2004 to 2008 is 6.23% to 5.50%. If the $120 million of 2006 pharmaceuticals R&D already includes that business’s $68 million of R&D restructuring, cleaned-up 2006 is about 5.87% rather than 5.56%, and 2007 is a further decline. Narrow R&D falls under every choice. The margin conclusion holds with or without stock-option expense. No reasonable basis turns the R&D ratio into a post-2005 recovery.

Why There’s No Grade

This site’s CEO rubric grades five fixed dimensions and requires each to be evidenced at medium confidence or better before an overall grade is given. This piece doesn’t meet that bar and isn’t meant to. There’s no peer set, no customer-outcome evidence and no review of governance, and the leadership change splits 2005. The filings also can’t tie a ratio to a specific person’s decision. A grade would claim more than the evidence supports, so none is given.

Reading Your Own Program’s Filings

  1. Fix the definitions first. List every reclassification in the notes before computing a ratio across years. 3M changed what counted as R&D three times in seven years.
  2. Separate the ratio from the dollars. A falling ratio with rising dollars is an allocation choice. A falling ratio with falling dollars is a cut.
  3. Strip currency and acquisitions from the denominator. In 2003 alone, currency added 5.2 points to 3M’s sales.
  4. Check the investment line critics ignore. At 3M, the deepest cut was capex, not research.
  5. Test sustainment for at least two years after the sponsor leaves. Durable gains are ratios that stay moved after the people who moved them are gone.

This is the discipline from Chapter 2 of my book 10-Minute Transformation: measure growth organically, so acquisitions and currency can’t flatter the number, and compare like with like on the same definitions and basis. When a one-time charge, an acquisition-accounting adjustment or a mix anomaly distorts a year, don’t judge that year on its own. Take out what you can identify and read the multi-year direction.

Other filings-first cases on this site: Gerstner’s First Three Years: Grade the Decisions, Not the Legend, Xerox 2000–2003: Three Bridges Before You Call It a Turnaround and Five Evidence Tests Before You Applaud a Turnaround: Kmart as the Negative Case, which includes a durability test.

Frequently Asked Questions

Did 3M cut R&D spending under its 2001–2005 efficiency program?

Only briefly. Research, development and related expense fell about 3%, from $1,101 million in 2000 to about $1,066 million in 2002 excluding restructuring, then rose to $1,143 million by 2004. As a share of sales it fell from about 6.6% to 5.7%, because sales grew faster.

Did R&D intensity recover at 3M after 2005?

Not by 2008. On a consistent basis, it was about 6.0% of sales in 2005, 5.6% in 2007 and 5.5% in 2008. Dollars rose, and 3M said ongoing non-pharmaceutical R&D grew about 11% in 2007, but sales grew as fast or faster.

Do 3M’s 10-Ks show its new-product sales ratio for these years?

None of the ten annual reports for fiscal 1999–2008 reviewed here reports one. Figures on the share of sales from recent products that appear in press coverage can’t be checked against these filings.

Limits

This is a reconstruction from ten public annual reports, read from outside the company. Research spending is an input, not a measure of invention, and the filings contain no output measure. Figures are compared only on matching definitions; where bases differ, both are shown. “Flagged items” are 3M’s own non-GAAP categories. There’s no peer comparison. Six-to-twelve-month effects aren’t visible in annual data. Fiscal 2005 spans a leadership change, and 2008 was a down year (organic volume −2.4%). Journalism is context only. Ratios are my calculations from the filed figures. Nobody is graded, and nothing here describes anyone’s motives or character. This is educational analysis, not investment advice.

Run the Test on Your Own Business

  • Book Todd to speak: bring this filings-first way of testing whether a cost program’s gains lasted to your board or leadership team. toddhagopian.com/speaking
  • Read the books: Stagnation Assassin, plus the forthcoming 10-Minute Transformation (Koehler Books, February 23, 2027). toddhagopian.com/book/
  • Free tool: find out whether your business is an ATM or a money pit with the ATM Test Scorecard.
  • Want to read 10-Minute Transformation before launch? Join the launch team.

Sources

  1. Minnesota Mining and Manufacturing Company, Form 10-K for fiscal 1999, filed February 18, 2000 (1999 figures as first reported). SEC EDGAR
  2. Minnesota Mining and Manufacturing Company, Form 10-K405 for fiscal 2000, filed February 20, 2001 (income statement; R&D; reclassification note; sales components; non-recurring items; 2001 initiatives; CEO election; capex; employment). SEC EDGAR
  3. Minnesota Mining and Manufacturing Company, Form 10-K405 for fiscal 2001, filed March 11, 2002 (income statement; R&D; adjusted ratios; 2001 initiative savings; capex; employment). SEC EDGAR
  4. 3M Company, Form 10-K for fiscal 2002, filed March 10, 2003 (restated sales; sales components; adjusted ratios; five initiatives; SG&A and employment statements; capex). SEC EDGAR
  5. 3M Company, Form 10-K for fiscal 2003, filed March 2, 2004 (special items by line; initiative and restructuring benefits; R&D realignment; sales components; risk factors; capex). SEC EDGAR
  6. 3M Company, Form 10-K for fiscal 2004, filed February 24, 2005 (2004 R&D on the original basis; operating income; initiatives; Corporate Research Laboratory; capex; employment). SEC EDGAR
  7. 3M Company, Form 10-K for fiscal 2005, filed February 21, 2006 (R&D for 2003–2005 and patent reclassification; R&D ratio statement; Six Sigma as a productivity tool; sales components; 2006 outlook; exhibit list; capex; employment). SEC EDGAR
  8. 3M Company, Form 10-K for fiscal 2006, filed February 26, 2007 (SFAS 123R-restated income statement; R&D for 2004–2006; in-process R&D and restructuring; pharmaceuticals sales; capex; employment). SEC EDGAR
  9. 3M Company, Form 10-K for fiscal 2007, filed February 15, 2008 (pharmaceuticals R&D; ongoing R&D statement; gain and restructuring summaries; organic sales components; capex; employment). SEC EDGAR
  10. 3M Company, Form 10-K for fiscal 2008, filed February 17, 2009 (R&D for 2006–2008; R&D statement; restructuring summary; sales components; capex; employment). SEC EDGAR
  11. Brian Hindo, “At 3M, A Struggle Between Efficiency And Creativity,” BusinessWeek, June 2007 (journalist interpretation, used as context only; capex and R&D claims checked against the 10-Ks above). Archived copy; Bloomberg
  12. Todd Hagopian, 10-Minute Transformation, Chapter 2, “The Three Velocity Metrics” (use organic growth, match definitions, and read the multi-year direction when one-time items distort a year). Koehler Books, forthcoming February 23, 2027. Paraphrased, not quoted.

Calculations are mine, from the filed figures cited. Educational analysis only.

About the Author

Todd Hagopian is VP of Product Strategy and Marketing and a business transformation author, speaker, and executive. His research is available as SSRN preprints. He is the author of the Turnaround Code Trilogy: The Unfair Advantage, Stagnation Assassin, and 10-Minute Transformation (February 23, 2027). More about Stagnation Assassins: About.